Bosch Berend Jan, Rossen John W A, Bartelink Willem, Zuurveen Stephanie J, de Haan Cornelis A M, Duquerroy Stephane, Boucher Charles A B, Rottier Peter J M
Virology Division, Department of Infectious Diseases and Immunology, Utrecht University, Faculty of Veterinary Medicine, and Institute of Biomembranes, Yalelaan 1, 3584 CL Utrecht, The Netherlands.
J Virol. 2008 Mar;82(5):2580-5. doi: 10.1128/JVI.02287-07. Epub 2007 Dec 12.
Peptides based on heptad repeat (HR) domains of class I viral fusion proteins are considered promising antiviral drugs targeting virus cell entry. We have analyzed the evolution of the mouse hepatitis coronavirus during multiple passaging in the presence of an HR2-based fusion inhibitor. Drug-resistant variants emerged as a result of multiple substitutions in the spike fusion protein, notably within a 19-residue segment of the HR1 region. Strikingly, one mutation, an A1006V substitution, which consistently appeared first in four independently passaged viruses, was the main determinant of the resistance phenotype, suggesting that only limited options exist for escape from the inhibitory effect of the HR2 peptide.
基于I类病毒融合蛋白七肽重复(HR)结构域的肽被认为是有前景的针对病毒细胞进入的抗病毒药物。我们分析了小鼠肝炎冠状病毒在基于HR2的融合抑制剂存在下多次传代过程中的进化情况。耐药变体是由于刺突融合蛋白中的多个替换而出现的,特别是在HR1区域的一个19个残基的片段内。引人注目的是,一个突变,即A1006V替换,在四个独立传代的病毒中始终首先出现,是耐药表型的主要决定因素,这表明逃避HR2肽抑制作用的选择有限。